ChemRar , an R&D institute and resident at the Skolkovo Foundation Biomedical Technologies Cluster, has created a platform to develop innovative drugs against Covid-19. The platform is now available to potential partners and the company is inviting international...
The company, Habilect, a resident of the Skolkovo Foundation Biomedical Technologies Cluster, received eight European certificates of quality for its rehabilitation system. The CE marking allows for the medical product to be exported to the European Union....
The company, Kromis , a resident of the biomedical technologies cluster of the Skolkovo Foundation, received a product license from the Ministry of Health of the Russian Federation for the antiviral medication “Avifavir.” Avifavir (the active...
SINGAPORE – A novel allosteric fibroblast growth factor receptor 2 (FGFR2) inhibitor, alofanib, has potent anti-tumour and antiangiogenic activity, according to the results of preclinical studies. The results were presented at the ESMO Asia 2016 Congress...
St. Petersburg, June 19, 2015 – On the first day of St. Petersburg International Economic Forum IBM signed a Memorandum of Understanding with ‘Skolkovo’ Foundation and the ‘First Oncology Research and Advisory Center’ (FORAC) for...
The upcoming summit of the SCO and BRICS in Ufa opened opportunities for communication and cooperation not only for politicians and businessmen, but also for scientists. With the support of the Government of the Republic of Bashkortostan, the Office of...
Dmitry Medvedev visited the first Skolkovo’s Innovation City building, the “Hypercube”, held the Modernization and Innovations Council meeting there and made a brief welcome speech at a biomed conference, held by the Skolkovo Foundation there...
The Skolkovo Institute of Science and Technology has announced a new program in Biomedical Science and Technology to educate leading graduate students. The university is inviting applications from entrepreneurial scientists in Russia and abroad for the 2013...